Challenge your understanding of motor fluctuation management in advanced PD. Explore continuous drug delivery pharmacology, pivotal trial outcomes, and patient selection for subcutaneous infusion.
5 questions
What pharmacologic advantage does 24-hour subcutaneous levodopa prodrug infusion offer vs oral immediate-release carbidopa/levodopa in advanced PD?
Correct Answer: C
Intermittent oral levodopa produces variable plasma concentrations that can contribute to motor fluctuations in advanced PD. Continuous subcutaneous infusion of water-soluble prodrugs provides more sustained levodopa exposure across the day and night.
https://pubmed.ncbi.nlm.nih.gov/40198538/
Pivotal Phase 3 trial: What was the primary efficacy finding at Week 12 for subcutaneous infusion vs oral IR carbidopa/levodopa?
Correct Answer: D
The pivotal Phase 3 trial showed subcutaneous infusion added 2.72 hours of ON time without troublesome dyskinesia vs 0.97 hours with oral IR carbidopa/levodopa (p=0.0083) — a nearly 3-fold improvement. OFF time was also reduced: -2.75 vs -0.96 hours (p=0.0054).
What is the key clinical advantage of non-surgical subcutaneous levodopa delivery in advanced PD?
Correct Answer: A
Continuous subcutaneous infusion provides device-aided therapy without the intracranial procedure required for DBS or the PEG-J placement required for intestinal levodopa infusion, offering a non-surgical route for continuous levodopa delivery.
ATMRD 2025 real-world analyses: What non-motor domain showed synergistic improvement with subcutaneous levodopa infusion?
Correct Answer: B
ATMRD 2025 real-world analyses showed subcutaneous infusion not only improved motor fluctuations but also synergistically enhanced sleep quality and health-related quality of life (PDQ-39 summary index and subdomains), reflecting benefits of stable overnight dopaminergic levels.
https://www.neurologylive.com/view/subcutaneous-foslevodopa-foscarbidopa-enhances-sleep-qol-synergistically-parkinsons
What are the most common adverse reactions with 24-hour subcutaneous levodopa prodrug infusion (at least 10%, more frequent than oral comparator)?
Per current prescribing information, the most common adverse reactions (at least 10% and more frequent than oral immediate-release carbidopa/levodopa) include infusion/catheter-site reactions, infusion/catheter-site infections, hallucinations, and dyskinesia. Serious adverse reactions are addressed separately in the prescribing information.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28e806e4-951c-40a9-9f0c-d0929caf054c
Start your journey with Neurologist Connect
